Kailera Therapeutics

KLRA

Market cap $3.03B

A company set up to develop Hengrui Pharma's weight-loss drugs has made a strong debut on the U.S. equity market, building confidence in the "NewCo" business model

WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the closing of its initial public offering of 44,921,875 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 5,859,375 additional shares, at the initial public offering price of $16.00 per share.